136 related articles for article (PubMed ID: 31074329)
1. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Banerjee S; Adhikari N; Amin SA; Jha T
J Biomol Struct Dyn; 2020 Mar; 38(5):1551-1564. PubMed ID: 31074329
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
3. Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors.
Banerjee S; Amin SA; Adhikari N; Jha T
J Biomol Struct Dyn; 2020 Nov; 38(18):5513-5525. PubMed ID: 31830865
[TBL] [Abstract][Full Text] [Related]
4. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
Banerjee S; Baidya SK; Adhikari N; Jha T
SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
[TBL] [Abstract][Full Text] [Related]
5. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
[TBL] [Abstract][Full Text] [Related]
6. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
[TBL] [Abstract][Full Text] [Related]
7. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
[TBL] [Abstract][Full Text] [Related]
8. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
[TBL] [Abstract][Full Text] [Related]
10. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
12. Designing potential HDAC3 inhibitors to improve memory and learning.
Amin SA; Adhikari N; Jha T; Ghosh B
J Biomol Struct Dyn; 2019 May; 37(8):2133-2142. PubMed ID: 30044204
[TBL] [Abstract][Full Text] [Related]
13. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry.
Rajaraman S; Balakrishnan R; Deshmukh D; Ganorkar A; Biswas S; Pulya S; Ghosh B
Future Med Chem; 2023 May; 15(10):885-908. PubMed ID: 37227732
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study.
Yao P; Gao Q; Wang Y; Yao Q; Zhang J
ChemMedChem; 2021 Jun; 16(12):1933-1944. PubMed ID: 33686739
[TBL] [Abstract][Full Text] [Related]
17. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
20. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
